Alkermes initiates multidose Stage 1 clinical research of ALKS 37 for OIC Alkermes.

announced the initiation of a multidose phase 1 clinical study of today ALKS 37, an active orally, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly known as opioid-induced constipation . The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers. Elliot Ehrich, Chief Medical Officer of Alkermes. These total outcomes will support a phase 2 clinical study of ALKS 37, that may assess the safety, tolerability and efficacy of ALKS 37 in individuals with OIC. The phase 2 study is expected to begin in the first half of calendar 2010.‘We have to do additional studies to determine whether this increased irritation in these older sufferers is due to either the fact that they don’t really take their medications, or that the irritation is fairly resistant to asthma treatment for some reason,’ he said. ‘Compared to that end, we are actually conducting a study to link airway irritation in patients over the age of 65 years of age to rates of medicine adherence.’.. ADHD symptoms might mask autism in small children Symptoms attributed to attention-deficit hyperactivity disorder might overshadow or mask autism spectrum disorder in very young children, a new study reveals.